One current vaccine candidate against Plasmodium vivax, targeting asexual blood stages, is the major merozoite surface protein-1 of P. vivax (PvMSP-1). Vaccine trials with PvMSP-119 and PvMSP-133 have succeeded in protecting monkeys and it has been shown that a large proportion of individuals naturally exposed to P. vivax infection, develop specific antibodies to PvMSP-119. In the present study, computational protein-protein docking was used to predict the structure of the antigenantibody complex between PvMSP119 and the Fab region of the G17.12 monoclonal antibody. This antibody does not inhibit erythrocyte invasion or MSP1 processing, but it recognises a discontinuous epitope on PfMSP119 that has been mapped to regions recognised by invasion-inhibiting antibodies. The molecular simulations were performed using, as starting structures, the Fab fragment of the P. falciparum MSP119-mAbG17.12 complex (pdb:1ob1) and the structure of the P. vivax MSP119 previously determined by homology modeling. The mAb was submitted to a docking procedure with antigen PvMSP119 using the programs PatchDock and FireDock to obtain an initial structure for the complex. A final optimization was performed with RosettaDock using a Monte Carlo algorithm. The final structure of the PvMP119-mAb17.12 complex shows that the antibody recognizes a discontinuous epitope that include segments on the first domain and some residues at the end of the second domain. The model provides valuable guidelines for future experimental work devoted to the identification of B-epitopes and synthesis of peptides with antigenic activity.
Introduction
Malaria today remains as one of the major causes of mortality and morbidity, with 3.2 billion people at risk, 300-500 million clinical cases and more than one million deaths annually [1] . Malaria is present in nearly 90 countries with 2.5 billion people exposed to infection by Plasmodium falciparum and Plasmodium vivax [2] . While P. falciparum prevails on the African continent [3] , P. vivax is the most widespread of the four Plasmodium species; it accounts for more than 50% of all malaria cases outside Africa and is responsible for significant morbidity in South American and Asian regions with a yearly estimate of 80 million cases [4] . During the last two decades, a number of reports have documented the development of resistance in P. vivax to several first-line antimalarial drugs [5] [6] [7] and the development of new strategies for combating the disease are urgently needed. Furthermore, wide geographic co-endemicity of P. falciparum and P. vivax results in an additional challenge for diagnosis and treatment.
The major merozoite surface protein-1 (MSP1) of the malaria parasite P. falciparum is of considerable interest as a vaccine candidate antigen [8, 9] . The C-terminal fragment of MSP1 (PfMSP1 19 ) enclosed two epidermal growth factor (EGF)-like domains and monoclonal antibodies binding MSP1 19 have the ability to inhibit the invasion of erythrocytes in vitro [10, 11] as well as in vivo in rodent models [12, 13] . It has been suggested that inhibition of MSP1 processing is the mechanism of action of these inhibitory antibodies. However, those antibodies specific for MSP1 19 that are not inhibitory can be divided into two classes: blocking antibodies that interfere with the binding of inhibitory antibodies and neutral antibodies which bind to MSP1 19 but neither inhibit invasion nor block the binding of inhibitory antibodies [14] [15] [16] .
Homologue PvMSP1 a 200 kDa protein expressed on the surface of P. vivax merozoite, is also a current vaccine candidate against asexual blood stages [17] . Studies on the naturally acquired humoral immune responses against P. vivax MSP1, showed that MSP1 C-terminal fragment of P. vivax (PvMSP1 19 ) is the most immunogenic portion of the molecule and evidence suggests that immunodominant domains interacting with protective antibodies are related to a structure also containing two epidermal growth factor (EGF)-like domains, like in PfMSP1 19 [18, 19] . Furthermore, vaccine trials with PvMSP1 19 and PvMSP1 33 have succeeded in protecting monkeys and it has been shown that a large proportion of individuals naturally exposed to P. vivax transmission, develop specific antibodies to PvMSP1 19 [20] [21] [22] .
To date most of the work on MSP1 has been focused on the Plasmodium falciparum protein. However, given the serious morbidity of malaria caused by Plasmodium vivax, and the wide co-endemicity of these two species, is particularly important for vaccine development to focus on P. vivax.
The crystal structures of the C-terminal domains of PcMSP-1 (P. cynomolgi) [23] , PkMSP-1 (P. knowlesi) [24] , and the solution structure of PfMSP-1 (P. falciparum) [25] , have been reported. The P. vivax C-terminal fragment of MSP1 has been studied using homology modeling [26] and NMR [27] . Moreover, the binding mode to specific antibodies was subject of different structural studies [28, 29] . The crystal structure of PfMSP1 19 in complex with the Fab-fragment of mAb G17.12 has been solved [28] and the interaction of PfMSP1 19 with malaria parasite inhibitory antibodies was studies by computational docking [29] . The mAb G17.12 does not inhibit erythrocyte invasion or MSP1 processing, but it recognizes a discontinuous epitope comprising 13 residues on the first epidermal growth factor (EGF)-like domain of PfMSP1 19 [28] . Because the overall folding of PvMSP1 19 is very similar to that previously reported for other C-terminal fragments of MSP-1, comparative studies could provide relevant information for the identification of epitopes helpful for the optimization of vaccines.
X-ray crystallization, while providing complete and high-resolution information, is time consuming and can be limited by the ability of the complex to form a crystal. An alternative is to use computational docking to predict the 3D structure of a protein complex. Our objective is to predict the structure of P. vivax MSP1 19 in complex with the Fab-fragment of mAb G17.12 by using a protocol that combines the protein docking programs PatchDock [30] and FireDock [31] , to obtain the starting structure and RossettaDock [32] to obtain the final model of the complex. In the docking field, protein flexibility and the absence of robust scoring functions present an important challenge. Due to these difficulties many docking methods apply a two-tier approach: coarse global search for feasible orientations that treats proteins as rigid bodies, followed by an accurate refinement stage that aims to introduce flexibility into the process. The PatchDock web server [30] performed rigid-body docking and then the results were sent to the FireDock web server that provides a method for flexible refinement and scoring the protein-protein docking solutions. The RosettaDock [32] method employs a low-resolution rigid-body Monte-Carlo search followed by an all-atom, simultaneous optimization of backbone displacement and backbone-dependent side chain rotamer conformations by using Monte-Carlo minimization.
In this work we propose a model for the three-dimensional structure of a Fab complex with the Cterminal fragment of merozoite surface protein-1 of P. vivax determined by computational docking. The structural data thus obtained reveal the presence of a discontinuous epitope that comprises residues on the first domain of PvMSP 19 and in the second domain of the protein.
Computational strategy
Modeling studies as well as the generation and analysis of the structures were performed running on AMD Athlon TM 64 X2 Dual Core Processor Driver for Windows XP (3.00 GHz HT). The publicly available web-servers for protein-protein docking PatchDock [30] , FireDock [31] and RosettaDock [32] were used for protein docking calculations. The structural alignment and analysis were performed using DeepView/SwissPdb-Viewer 3.7 (Glaxo-SmithKline) [33] . Molecular figures were prepared using WebLab ViewerLite 3.20. The CASTp server was used for identification of the binding sites [34] . CASTp provides identification and analytical measurements of surface accessible pockets, for proteins and other molecules, which can be used to guide protein-protein interactions.
To obtain the starting structures, the crystal structure of the Fab fragment (D and E chains) of the P. falciparum MSP1 19 -FabG17.12 complex (pdb:1ob1) [28] and the structure of the P. vivax MSP1 19 previously determined by homology modeling [26] , were send to the PatchDock web server. PatchDock is a geometry-based molecular docking algorithm and each candidate solution is evaluated by a scoring function that considers both geometric fit and atomic desolvation energy. The RMSD (root mean square deviation) default clustering was applied to discard redundant solutions [30] . The FireDock web server was used for refinement and re-scoring the 1000 rigid-body protein-protein docking solutions thus obtained. FireDock algorithm includes a Side-chain optimization followed by a Rigid-body minimization by a Monte Carlo technique that attempts to optimize an approximate binding energy and a final ranking stage is performed according to a binding energy function [31] . This protocol was performed 10 times to assess the statistical trends of the solutions. The best average PvMSP1 19 -FabG17.12 complex model was used as starting structure for a further refinement with RossettaDock. The RosettaDock method employs a low-resolution rigid-body Monte-Carlo search followed by an all-atom, simultaneous optimization of backbone displacement and backbone-dependent side chain rotamer conformations by using MonteCarlo minimization. The resulting models are ranked by using a scoring function dominated by van der Waals interactions, implicit Gaussian salvation, orientation-dependent hydrogen bonding, side-chain rotamer probabilities and low-weighted electrostatics energy [32, 35] . To generate an ensemble of models, the default 1000 independent simulations were carried out. The 10 best-scoring structures from the run ranked by energy were inspected. The final antibody-antigen complex was checked with ProCheck.
The docking of mAb G17.12 with antigen PfMSP1 19 was performed as a test case to check the reliability of the docking procedure. The model of the complex thus obtained was compared with the crystal structure previously reported. 
Results and discussion
The prediction of antibody-antigen complex structures is critical to rational vaccine design. Moreover the design process will benefit from understanding the influence of the antigenic protein individual residues on the calculated binding energy. In the present work we performed a molecular docking calculation with the PvMSP1 19 and the Fab fragment of the monoclonal antibody G17.12 to investigate which residues are especially important as binding epitopes.
The overall protocol for the determination of the PvMSP1 19 -mAbG17.12 complex includes, as an initial step, the use in combination of PatchDock and FireDock to obtain the starting structure. We identified the high reproducibility of the protocol when the best solution of each run, as judged by the value of their global energy, was structurally compared and no significant RMSD deviation between them was observed. The model with the lower global energy was saved for further refinement and validation.
Final refinement was performed with RosettaDock, as described in Section 2. The power of RosettaDock method has been repeatedly and successfully tested in CAPRI (Critical Assessment of PRedicted Interactions) blind tests on diverse targets including antigen-antibody pairs, enzyme-inhibitor pairs and regulatory proteins [36] . As a result of perturbation studies on the PvMSP1 19 -mAbG17.12 complex, the server returns a plot of the energies of 1000 structures created during the docking run versus the RMSD from the starting input conformation (Fig. 1) . The presence of the 'docking funnel', where many low-scoring decoys have similar RMSD values (indicating similar conformations) can be used as convergence criterion and, by extension, to generate confidence in the provided solutions. The lowest energy model obtained by RosettaDock was selected as our prediction for the PvMSP1 19 -mAbG17.12 complex. The quality of the model was checked with ProCheck. The structure satisfied the tests; in the Ramachandran plot, 96.5% of the non-glycine residues lie within the most favored and additionally allowed regions indicating a good overall geometry of the complex. Figure 2 shows the relative positions of PvMSP1 19 and the mAbG17.12 in the final model and Table 1 shows the residue interface contacts. The interface incorporates 16 residues of the first domain of PvMSP1 19 , segments 1-9, 12-17, 20, and 6 residues of the second domain, segments 80-84 and 90, 91. There are seven hydrogen bonds across the interface that accounts for the stability of the complex: I8-H93L, A16-S30L, S91-Y96H, V12-S29L, T6-Y96L, E80-R98H and S3-Y96L (in decreasing order of calculated Rosetta hydrogen bonding energy, where Y96L refers to the Tyr at residue position 96 of the light chain, and so on). Several residue pairs also make extensive hydrophobic contacts: E4-W50H, S3-Y96L, E4-Q58H, S2-Y97H, E80-R98H, S91-T31H, M1-Y97H, I8-H93L, and S3-W50H (in decreasing order of Rosetta van der Waals attractive energies). The intermolecular contacts that contribute the most to the total binding energy in the Rosetta calculations are S3-Y96L, S3-W50H and E80-R98H. As follows from the analysis above, the mAbG17.12 recognizes a discontinuous epitope on the first domain of PvMSP 19 and another one in the second domain of the protein.
Previously, when the structure of PvMSP1 19 was determined by homology modeling [26] , the threedimensional structures of PvMSP1 19 and PfMSP1 19 were compared and a less compact structure and a main binding pocket, well suited for protein-protein interactions, were observed for the first domain of the P. vivax protein. To add in proof of the previous observation, a careful comparison was performed between our P. vivax antigen-antibody model and the results of two different structural studies of P. falciparum MSP1 19 complexes [28, 29] . Table 2 shows the residues that are recognized within the S2  I 2  R25  S3  E26  E4  Q4  C28  H5  H5  Y34  Y34  T6  Q6  G38  C7  D39 D39  I8  V8  V8  K40  K40  D9  K9  K9  C41  Q11  Q11 Q11  E43  V12  C12  E80  P13  P13  P13  L82  D14  Q14  Q14 Q14  F83  N15  N15  N15  E84  Y84  A16  F87  A17  S90  R20  S91 PvMSP1 19 -mAbG17.12 modeled structure and those of the different PfMSP 19 -mAb structures.
In the X-ray structure of the PfMSP1 19 -mAbG17.12 a very similar discontinuous epitope is recognized on the first EGF like domain of the protein [28] (Table 2 ). This region is particularly interesting because several growth inhibitory monoclonal antibodies (mAb) bind to the first EGF domain of the PfMSP-1 19 [37] and, for some of these antibodies, a target epitope has been located on the N-terminal EGF-like domain of the PfMSP1 19 [38] . Moreover, mutagenesis studies established that residues R20, E24 and E26 affect the binding of invasion-inhibiting and blocking antibodies [38] . Although the mAbG17.12 is not blocking or inhibitory it recognizes an epitope that includes, among others, some of the residues mentioned above, for both PvMSP1 19 and PfMSP1 19 complexes.
In the computational docking study about the interaction of PfMSP1 19 with two strongly inhibitory antibodies (designated 12.8 and 12.10) two slightly different binding modes were determined for the two antibodies [29] . The PfMP1 19 -mAb12.10 complex shows that the antibody recognizes a discontinuous epitope on the first domain and some residues at the end of the second domain [29] . However, for the complex PfMSP1 19 -mAb12.8 the antigen is anchored mainly through its first EGF-like domain. These observations are in agreement with previous experimental evidences that pointed out that antibody 12.10 can only binds in the presence of both PfMSP1 19 EGF domains; while for 12.8 the presence of domain 1 is sufficient to observe binding [37] .
From the previous comparison it is clear that our computed structure shows a slightly different binding mode to that observed in the PfMSP1 19 complexes. Some of the residues of PvMSP1 19 in direct contact with G17.12 correspond to sites that are also recognized in the crystal structure of the PfMSP1 19 -mAbG17.12 and in the docked complex PfMSP1 19 -mAb12.8, but it is noteworthy that the P. vivax protein is anchored to the antibody through residues that are also recognized in the computed complex of PfMP1 19 with the inhibitory antibody 12.10. Supporting these observations, several studies show the possibility of cross-recognition between-species [39] [40] [41] .
These results can be considered as an extremely useful, inexpensive and rapid alternative to identify potential B-cell epitopes through the analysis of the computationally determined PvMSP1 19 -mAbG17.12 complex, especially because no X-ray or NMR studies are available. The model will also provide a working hypothesis for further analysis though it is consistent with previously reported studies that showed that the C-terminal fragment of the PvMSP1 is highly immunogenic and that the immunodominant domains interacting with protective antibodies are related to the EGF domains.
Conclusions
The three-dimensional structure of the Fab fragment of the monoclonal antibody G17.12 complex with the C-terminal fragment of merozoite surface protein-1 of Plasmodium vivax was determined by computational docking. A successfull docking procedure that combines PatchDock, FireDock and RossettaDock, to obtain the final model of the complex, was applied. The PvMP1 19 -mAb17.12 complex shows that the antibody recognizes a discontinuous epitope that includes segments on the first domain and some residues at the end of the second domain. There are interesting similarities between our model and the complex of PfMP1 19 with the inhibitory antibody 12.10 previously reported [29] .
